Clinical Trials in Baltimore

Showing 5101-5120 of 23,476 trials

Post-transplant Flotetuzumab for AML

NCT05506956

The purpose of this research study is to determine if the study drug, flotetuzumab, is safe and tolerable when given to participants with acute myeloid leukemia (AML) that has relapsed after transplant.

Leukemia, Myeloid, Acute

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins3 participantsStarted Oct 2022

Baltimore, Maryland, United States

TERMINATEDPhase 1< 1 mile

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

NCT05231668

SAR439459 is a human anti-Transforming growth factor β (TGFβ) monoclonal antibody. This phase 1 clinical study investigates the safety, tolerability, and activity of a single dose of SAR439459 in adult participants with OI. Participants will receive a single IV dose of SAR439459 with safety, pharmacokinetic (PK), and pharmacodynamic (PD) assessments over 24 weeks. There will be up to 3 dose cohorts. In addition to safety, tolerability, and PK assessments, bone mineral density (BMD) will be evaluated by dual-energy Xray absorptimetry (DXA) scan and a series of blood biomarkers will be monitored to document pharmacodynamic effects of the single dose of SAR439459.

Osteogenesis Imperfecta

Sanofi16 participantsStarted Aug 2022

Los Angeles, California, United States • New Haven, Connecticut, United States • Indianapolis, Indiana, United States +10 more locations

Post-transplant Flotetuzumab for AML

Single Ascending Dose Study of SAR439459 in Adults With Osteogenesis Imperfecta (OI)

Find Trials by Condition in Baltimore

PKD Clinical and Translational Core Study

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer

A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug

OMEGA: Outcome Measures in Eosinophilic Gastrointestinal Disorders Across the Ages

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer

Device Feasibility and Acceptability to Improve Insomnia in Cancer

Tailored vs. Anatomical Ablation Strategy for Persistent Atrial Fibrillation

A Study of Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

A Study Comparing ATB200/AT2221 With Alglucosidase Alfa/Placebo in Adult Subjects With Late-onset Pompe Disease

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older

Effectiveness of Remote Foot Temperature Monitoring

Study of Lademirsen (SAR339375) in Patients With Alport Syndrome

Use of Dalfampridine in Primary Lateral Sclerosis

A Study Comparing Venetoclax and Azacitidine Plus Cusatuzumab to Venetoclax and Azacitidine in Newly Diagnosed AML Ineligible for Intensive Therapy

A Study to Assess the Safety and Tolerability of BMS-986158 Alone and in Combination With Either Ruxolitinib or Fedratinib in Participants With Blood Cancer (Myelofibrosis)

A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors

SPRINT: Signature for Pain Recovery IN Teens

A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)